ADCETRIS

Indicaton

SeaGen's lead product ADCETRIS® (brentuximab vedotin) is marketed in over 70 countries worldwide for the treatment of CD30-expressing lymphomas, in collaboration with Takeda Pharmaceutical Company Limited.

Therapeutic indications

Oncology

Type of product

Antibody

Table

Phase

Marketed
Partnering status

Partnered
Partner

Takeda Pharmaceutical Company Limited.
Available in

EU, US, LATAM, JAPAC, Switzerland

You may also be interested in

OligoPhore / SemaPhore / CycloPhore Peptide-Based RNA Delivery Platforms

Delivers siRNA, antisense oligonucleotides, linear or circular mRNA and other RNA modalities to extrahepatic tissues - demonstrated across various indications in oncology (e.g. PDAC, breast cancer, ovarian cancer, lung cancer, melanoma, ATLL, TME), and inflammatory / autoimmune diseases (e.g. OA, RA, enterocolitis), CV (e.g. atherosclerosis, aortic aneurysm)

Discovery

SOT201 (Immunocytokine, PD-1 x IL-15)

solid tumors

Phase I started

SOT109 (Antibody-Drug Conjugate)

solid tumors, mainly colorectal

Discovery